Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 5 | 3 |
| List of Tables | 7 | 1 |
| List of Figures | 7 | 1 |
| Statins Market to 2018 - Introduction | 8 | 1 |
| Statins Market to 2018 - Global Statins Market | 9 | 16 |
| Introduction | 9 | 1 |
| Global Market Forecast | 10 | 2 |
| Branded and Generic Market Share | 12 | 1 |
| Annual Cost of Treatment | 13 | 1 |
| Treatment Usage Patterns | 14 | 1 |
| Disease Population | 15 | 1 |
| Treatment Seeking Population | 15 | 1 |
| Diagnosed Population | 15 | 1 |
| Prescription Population | 15 | 1 |
| Drivers and Restraints to the Statins Market | 16 | 1 |
| Drivers to the Statins Market | 16 | 1 |
| Rise in Diseased Population with Improved Awareness of Dyslipidemia is Expected to Drive Growth of the Statins Market | 16 | 1 |
| Restraints to the Statins Market | 17 | 1 |
| Poor Patient Compliance and Poor Diagnosis are Negatively Impacting the Statins Market | 17 | 1 |
| Increasing Trend towards the Use of Non-statins and Combination Therapies May Affect the Prescription Share of Statins | 17 | 1 |
| Weak R&D Product Pipeline for Statins Due to a Shift of Focus towards Other Targets | 17 | 1 |
| Generic Availability of the Leading Brands in the Forecast Period will Restrain Growth of the Statins Market | 18 | 1 |
| Cost Containment Policies and Growing Generics Usage are Expected to Lead to a Decline in the Prices of Statins | 18 | 1 |
| Major Marketed Products | 19 | 1 |
| Crestor (rosuvastatin calcium) | 19 | 1 |
| Lipitor (atorvastatin calcium) | 20 | 1 |
| Vytorin (ezetimibe/simvastatin) | 21 | 1 |
| Zocor (simvastatin) | 22 | 1 |
| Livalo (pitavastatin calcium) | 22 | 1 |
| Lescol XL (fluvastatin sodium) | 23 | 1 |
| Pravachol (pravastatin sodium) | 24 | 1 |
| Statins Market to 2018 - Statins Market in the US | 25 | 5 |
| Market | 25 | 2 |
| Annual Cost of Therapy (ACT) | 27 | 1 |
| Treatment Usage Pattern | 28 | 1 |
| Diseased Population | 29 | 1 |
| Treatment Seeking Population | 29 | 1 |
| Diagnosed Population | 29 | 1 |
| Patients on Statins Therapy | 29 | 1 |
| Statins Market to 2018 - Statins Market in the Top Five Countries of Europe | 30 | 6 |
| Market | 30 | 3 |
| Annual Cost of Therapy | 33 | 1 |
| Treatment Usage Pattern | 34 | 1 |
| Diseased Population | 35 | 1 |
| Treatment Seeking Population | 35 | 1 |
| Diagnosed Population | 35 | 1 |
| Patients on Statins Therapy | 35 | 1 |
| Statins Market to 2018 - Statins Market in Japan | 36 | 6 |
| Market | 36 | 2 |
| Annual Cost of Therapy | 38 | 2 |
| Treatment Usage Pattern | 40 | 1 |
| Diseased Population | 41 | 1 |
| Treatment Seeking Population | 41 | 1 |
| Diagnosed Population | 41 | 1 |
| Patients on Statins Therapy | 41 | 1 |
| Statins Market to 2018 - Product Pipeline Anlaysis | 42 | 1 |
| Introduction | 42 | 1 |
| Pipeline Analysis | 42 | 1 |
| Statins Market to 2018 - Competitive Landscape | 43 | 5 |
| Pfizer Inc. | 44 | 1 |
| Company Overview | 44 | 1 |
| SWOT Analysis | 44 | 1 |
| AstraZeneca PLC (AstraZeneca) | 45 | 1 |
| Company Overview | 45 | 1 |
| SWOT Analysis | 45 | 1 |
| Merck &Co Inc | 46 | 1 |
| Company Overview | 46 | 1 |
| SWOT Analysis | 46 | 1 |
| Novartis AG (Novartis) | 47 | 1 |
| Company Overview | 47 | 1 |
| SWOT Analysis | 47 | 1 |
| Statins Market to 2018 - Strategic Consolidation | 48 | 4 |
| Merger and Acquisition (M&A) Deals | 48 | 1 |
| On November 7, 2008, Daiichi Sankyo Acquires Majority Stake in Ranbaxy Laboratories. | 49 | 1 |
| On August 24, 2010, Pharmena Acquires Remaining Interest in Cortria. | 49 | 1 |
| Licensing Deals | 49 | 1 |
| Licensing Deals by Geography | 49 | 1 |
| On August 14, 2008, AstraZeneca Entered into Agreement with Abbott Laboratories. | 50 | 1 |
| On December 23, 2009, Eli Lilly Entered into Licensing Agreement with Kowa Pharmaceuticals. | 50 | 1 |
| On April 7, 2010, Recordati Entered into Licensing Agreement with Laboratorios Del Dr. Esteve. | 50 | 1 |
| Co-development Deals | 51 | 1 |
| On January 7, 2008, Genfit Extended Co-development Agreement with Pierre Fabre | 51 | 1 |
| On June 17, 2008, AstraZeneca Enters into an Agreement with Columbia University Medical Center | 51 | 1 |
| Statins Market to 2018 - Appendix | 52 | 9 |
| Market Definitions | 52 | 1 |
| Abbreviations | 52 | 3 |
| Bibliography | 55 | 1 |
| Research Methodology | 56 | 5 |
| Coverage | 56 | 1 |
| Secondary Research | 56 | 1 |
| Primary Research | 57 | 1 |
| Therapeutic Landscape | 57 | 1 |
| Epidemiology-based Forecasting | 58 | 1 |
| Market Size by Geography | 59 | 1 |
| Geographical Landscape | 60 | 1 |
| Pipeline Analysis | 60 | 1 |
| Competitive Landscape | 60 | 1 |
| Expert Panel Validation | 60 | 1 |
| Contact Us | 60 | 1 |
| Disclaimer | 60 | 1 |